{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T16:07:38Z","timestamp":1764259658280},"reference-count":13,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1586\/erp.09.1","type":"journal-article","created":{"date-parts":[[2009,4,30]],"date-time":"2009-04-30T11:41:40Z","timestamp":1241091700000},"page":"117-121","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia"],"prefix":"10.1586","volume":"9","author":[{"given":"Matthew J","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A","family":"Scuffham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2014,1,9]]},"reference":[{"key":"CIT0001","unstructured":"O\u2019Brien S. MIMS guide to chronic myeloid leukaemia. London, UK (2000)."},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6330","volume":"6","author":"Garside","year":"2002","journal-title":"Health Technol. Assess."},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011573"},{"key":"CIT0004","unstructured":"Aoki E, Kantarjian H, O\u2019Brien Set al.Correlation of different responses to imatinib on survival of patients with chronic myelogenous leukemia in accelerated and blast phase. Presented at:46th Annual Meeting of the American Society of Hematology. San Diego, CA, USA, 4\u20137 December (2004) (Abstract 1103)."},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"CIT0006","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"CIT0007","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"CIT0008","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"CIT0009","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1056\/NEJMc053425","volume":"354","author":"Assouline","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"CIT0010","doi-asserted-by":"crossref","unstructured":"Levy AR, Szabo SM, Tabberer M, and Davis C. Utility values for health states for chronic myelogenous leukaemia (CML): estimates from laypersons in Australia, the United Kingdom (UK) and Canada. Presented at:ISPOR European Conference. Dublin, Ireland, 20\u201323 October 2007.","DOI":"10.1016\/S1098-3015(10)65228-X"},{"key":"CIT0011","unstructured":"Taylor M. The relationship between short-term response and long-term costs and benefits in the treatment of chronic myelogenous leukaemia. Presented at:ISPOR International Conference. Arlington, VA, USA, 21\u201325 May 2007."},{"key":"CIT0012","unstructured":"Holowiecki J, Konopka L, Kopera Met al.; Polish Adult Leukemia Group. Efficacy of imatinib in patients with chronic myeloid leukemia in late chronic phase who are hematologically or cytogenetically resistant or refractory to interferon \u03b1. Phase II study of the Polish Adult Leukemia Group. Presented at:45th Annual Meeting and Exposition of the American Society of Hematology. San Diego, CA, USA, 6\u20139 December 2003."},{"key":"CIT0013","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","volume":"26","author":"Shah","year":"2008","journal-title":"J. Clin. Oncol."}],"container-title":["Expert Review of Pharmacoeconomics & Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1586\/erp.09.1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,4]],"date-time":"2021-10-04T18:15:45Z","timestamp":1633371345000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1586\/erp.09.1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,1,9]]},"published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1586\/erp.09.1"],"URL":"https:\/\/doi.org\/10.1586\/erp.09.1","relation":{},"ISSN":["1473-7167","1744-8379"],"issn-type":[{"value":"1473-7167","type":"print"},{"value":"1744-8379","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}